#United States #Newport News #Dilon Technologies #HEMOBLAST #MarginProbe

Dilon Technologies Raises $9 Million for Expansion

In a significant move to strengthen its position in the medical device arena, Dilon Technologies®, a pioneer in advanced surgical products, has successfully closed a $9 million growth capital financing deal with JGB Management Inc. This funding is poised to support Dilon’s ongoing double-digit revenue growth and enhance its operational capabilities in delivering innovative solutions for biosurgery and breast cancer treatment.

Advancing Surgical Innovation

Dilon Technologies is renowned for its robust portfolio of medical devices that are transforming clinical outcomes in surgical settings. CEO George Makhoul expressed pride in the partnership with JGB, highlighting that this collaboration will empower the company to further its mission of providing evidence-based surgical solutions to healthcare providers globally.

One of Dilon’s standout offerings is the HEMOBLAST Bellows®, an innovative hemostatic agent indispensable in various surgical scenarios, including cardiac, orthopedic, and general procedures. Notably, this product is the only FDA-approved solution specifically intended for the management of minimal to moderate bleeding, now utilized in hundreds of hospitals across the United States. As hospitals aim to minimize complications associated with bleeding during surgeries, HEMOBLAST Bellows® continues to lead the way in redefining practices in surgical hemostasis.

Another key product from Dilon is the MarginProbe®, a device that provides real-time assessment of breast cancer margins during surgery. This technology has been pivotal in significantly reducing the necessity for corrective surgeries, evidenced by clinical studies citing a 25% to 80% decrease in re-excision rates. A recent study published in The American Surgeon Journal reported a remarkable 42% reduction in re-excision for patients diagnosed with Ductal Carcinoma In Situ (DCIS). To further enhance its offerings, a next-generation version of MarginProbe® has recently been submitted to the FDA, with approvals expected by year-end 2025.

Leading the Charge in Lymphatic Mapping

Dilon Technologies also excels with its Navigator™ Gamma Probe product line, revered for its effectiveness in radio-guided lymphatic mapping and tumor localization. The market-leading tool continues to gain traction and is set to launch a new, enhanced version by late 2025, further consolidating its leadership in this crucial medical device segment.

Brett Cohen, CEO of JGB Management Inc., affirmed their commitment to supporting Dilon’s mission, stating, “We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide.” This partnership is expected to fuel Dilon’s growth trajectory as it expands its suite of innovative products, enhancing surgical capabilities and ultimately improving patient care.

About Dilon Technologies

Dilon Technologies, Inc., based in Newport News, Virginia, is a commercially active medical device firm specializing in developing, manufacturing, and marketing innovative medical technologies related to hemostasis, cancer detection, and airway management. The company’s expanding surgical portfolio currently highlights:

• - HEMOBLAST Bellows®: The first and only FDA-approved powder hemostatic agent effective for minimal to moderate bleeding.
• - MarginProbe®: A state-of-the-art, real-time margin assessment device specifically designed for surgical applications in breast cancer.
• - Navigator™ System: An advanced surgical gamma probe focusing on tumor localization and lymphatic mapping.
• - TrueView 100 Pro: An analyzer for surgical specimens, ensuring effective and accurate intraoperative assessments.
• - CoPilot VL+®: A compact and portable video laryngoscope crucial for airway visualization.

With this financial backing, Dilon Technologies is set to further its commitment to providing cutting-edge surgical solutions that prioritize patient outcomes and healthcare efficacy. For more information about Dilon Technologies and its innovative products, visit www.dilon.com.